Can cellular models revolutionize drug discovery in Parkinson's disease?

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 11, 2009, Pages 1043-1051

  Schüle, Birgitt ^a   Pera, Renee A Reijo ^b   Langston, J William ^a  

^a PARKINSON S INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cellular disease model; iPSC; Neurodegeneration; Nuclear reprogramming; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMINO ACID DECARBOXYLASE; ATM PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME C; CYTOCHROME C OXIDASE; DJ 1 PROTEIN; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; LEUCINE RICH REPEAT KINASE 2; NEUROTROPHIN 3 RECEPTOR; NUCLEAR RECEPTOR RELATED FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 4; PARKIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR SOX2; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; WNT1 PROTEIN; WNT3A PROTEIN;

CELL CULTURE; CELL DIFFERENTIATION; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DRUG RESEARCH; DRUG SCREENING; EMBRYONIC STEM CELL; FIBROBLAST; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HYBRID CELL; MESENCHYMAL STEM CELL; NERVE DEGENERATION; NEURAL STEM CELL; NEUROBLASTOMA CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STROKE; ANIMAL; BIOLOGICAL MODEL; CELL LINE; DRUG DEVELOPMENT; METABOLISM; METHODOLOGY;

ANIMALIA;

ANIMALS; CELL LINE; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PARKINSON DISEASE; PLURIPOTENT STEM CELLS;

EID: 73349129099     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.08.014     Document Type: Review

References (131)

1. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., and Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68 (2007) 384-386
2. Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 59 (2006) 591-596
3. Poewe W. Non-motor symptoms in Parkinson's disease. Eur. J. Neurol. 15 Suppl. 1 (2008) 14-20
4. Hawkes C.H., Del Tredici K., and Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol. Appl. Neurobiol. 33 (2007) 599-614
5. Laywell E.D., Kukekov V.G., and Steindler D.A. Multipotent neurospheres can be derived from forebrain subependymal zone and spinal cord of adult mice after protracted postmortem intervals. Exp. Neurol. 156 (1999) 430-433
6. Kukekov V.G., Laywell E.D., Suslov O., Davies K., Scheffler B., Thomas L.B., O'Brien T.F., Kusakabe M., and Steindler D.A. Multipotent stem/progenitor cells with similar properties arise from two neurogenic regions of adult human brain. Exp. Neurol. 156 (1999) 333-344
7. Palmer T.D., Schwartz P.H., Taupin P., Kaspar B., Stein S.A., and Gage F.H. Cell culture. Progenitor cells from human brain after death. Nature 411 (2001) 42-43
8. Walton N.M., Sutter B.M., Chen H.X., Chang L.J., Roper S.N., Scheffler B., and Steindler D.A. Derivation and large-scale expansion of multipotent astroglial neural progenitors from adult human brain. Development 133 (2006) 3671-3681
9. Otto D., and Unsicker K. FGF-2-mediated protection of cultured mesencephalic dopaminergic neurons against MPTP and MPP+: specificity and impact of culture conditions, non-dopaminergic neurons, and astroglial cells. J. Neurosci. Res. 34 (1993) 382-393
10. Mytilineou C., Cohen G., and Heikkila R.E. 1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture. Neurosci. Lett. 57 (1985) 19-24
11. Fath T., Ke Y.D., Gunning P., Gotz J., and Ittner L.M. Primary support cultures of hippocampal and substantia nigra neurons. Nat. Protoc. 4 (2009) 78-85
12. Sanchez-Ramos J.R., Michel P., Weiner W.J., and Hefti F. Selective destruction of cultured dopaminergic neurons from fetal rat mesencephalon by 1-methyl-4-phenylpyridinium: cytochemical and morphological evidence. J. Neurochem. 50 (1988) 1934-1944
13. Perrier A.L., and Studer L. Making and repairing the mammalian brain-in vitro production of dopaminergic neurons. Semin. Cell Dev. Biol. 14 (2003) 181-189
14. Bunney B.S., Chiodo L.A., and Grace A.A. Midbrain dopamine system electrophysiological functioning: a review and new hypothesis. Synapse 9 (1991) 79-94
15. Elsworth J.D., and Roth R.H. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. Exp. Neurol. 144 (1997) 4-9
16. Mendez I., Sanchez-Pernaute R., Cooper O., Vinuela A., Ferrari D., Bjorklund L., Dagher A., and Isacson O. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128 (2005) 1498-1510
17. German D.C., Manaye K.F., Sonsalla P.K., and Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. N. Y. Acad. Sci. 648 (1992) 42-62
18. Lynd-Balta E., and Haber S.N. The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum. Neuroscience 59 (1994) 625-640
19. Chung S., Hedlund E., Hwang M., Kim D.W., Shin B.S., Hwang D.Y., Jung Kang U., Isacson O., and Kim K.S. The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons. Mol. Cell. Neurosci. 28 (2005) 241-252
20. Chung S., Sonntag K.C., Andersson T., Bjorklund L.M., Park J.J., Kim D.W., Kang U.J., Isacson O., and Kim K.S. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur. J. Neurosci. 16 (2002) 1829-1838
21. Moore D.J., and Dawson T.M. Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. Curr. Neurol. Neurosci. Rep. 8 (2008) 288-296
22. Di Monte D.A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurol. 2 (2003) 531-538
23. Klein C., and Schlossmacher M.G. Parkinson disease, 10 years after its genetic revolution. Multiple clues to a complex disorder. Neurology 69 22 (2007) 2093-2104
24. Bras J.M., and Singleton A. Genetic susceptibility in Parkinson's disease. Biochim. Biophys. Acta 1792 7 (2009) 597-603
25. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E., Farrer M., Hardy J., Duff K., Przedborski S., and Di Monte D.A. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8 (2001) 535-539
26. Chen L., Cagniard B., Mathews T., Jones S., Koh H.C., Ding Y., Carvey P.M., Ling Z., Kang U.J., and Zhuang X. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J. Biol. Chem. 280 (2005) 21418-21426
27. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., and Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279 (2004) 18614-18622
28. Manning-Bog A.B., and Langston J.W. Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox. Res. 11 (2007) 219-240
29. Pahlman S., Hoehner J.C., Nanberg E., Hedborg F., Fagerstrom S., Gestblom C., Johansson I., Larsson U., Lavenius E., Ortoft E., et al. Differentiation and survival influences of growth factors in human neuroblastoma. Eur. J. Cancer 31A (1995) 453-458
30. Pahlman S., Mamaeva S., Meyerson G., Mattsson M.E., Bjelfman C., Ortoft E., and Hammerling U. Human neuroblastoma cells in culture: a model for neuronal cell differentiation and function. Acta Physiol. Scand. Suppl. 592 (1990) 25-37
31. Presgraves S.P., Ahmed T., Borwege S., and Joyce J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 5 (2004) 579-598
32. Lopez-Carballo G., Moreno L., Masia S., Perez P., and Barettino D. Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J. Biol. Chem. 277 (2002) 25297-25304
33. Fernandes N.D., Sun Y., and Price B.D. Activation of the kinase activity of ATM by retinoic acid is required for CREB-dependent differentiation of neuroblastoma cells. J. Biol. Chem. 282 (2007) 16577-16584
34. Cheung Y.T., Lau W.K., Yu M.S., Lai C.S., Yeung S.C., So K.F., and Chang R.C. Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 30 (2009) 127-135
35. Pleasure S.J., and Lee V.M. NTera 2 cells: a human cell line which displays characteristics expected of a human committed neuronal progenitor cell. J. Neurosci. Res. 35 (1993) 585-602
36. Newman M.B., Misiuta I., Willing A.E., Zigova T., Karl R.C., Borlongan C.V., and Sanberg P.R. Tumorigenicity issues of embryonic carcinoma-derived stem cells: relevance to surgical trials using NT2 and hNT neural cells. Stem Cells Dev. 14 (2005) 29-43
37. Newcomb J.D., Janowski M., Zigova T., Saporta S., McGrogan M.P., Sanberg P.R., and Willing A.E. A comparison of dopaminergic cells from the human NTera2/D1 cell line transplanted into the hemiparkinsonian rat. Life Sci. 81 (2007) 441-448
38. Willing A.E., Sudberry J.J., Othberg A.I., Saporta S., Poulos S.G., Cameron D.F., Freeman T.B., and Sanberg P.R. Sertoli cells decrease microglial response and increase engraftment of human hNT neurons in the hemiparkinsonian rat striatum. Brain Res. Bull. 48 (1999) 441-444
39. Willing A.E., Zigova T., Milliken M., Poulos S., Saporta S., McGrogan M., Snable G., and Sanberg P.R. Lithium exposure enhances survival of NT2N cells (hNT neurons) in the hemiparkinsonian rat. Eur. J. Neurosci. 16 (2002) 2271-2278
40. Baker K.A., Hong M., Sadi D., and Mendez I. Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease. Exp. Neurol. 162 (2000) 350-360
41. Kondziolka D., Wechsler L., Gebel J., DeCesare S., Elder E., and Meltzer C.C. Neuronal transplantation for motor stroke: from the laboratory to the clinic. Phys. Med. Rehabil. Clin. N. Am. 14 (2003) S153-S160 xi
42. Schwartz C.M., Spivak C.E., Baker S.C., McDaniel T.K., Loring J.F., Nguyen C., Chrest F.J., Wersto R., Arenas E., Zeng X., Freed W.J., and Rao M.S. NTera2: a model system to study dopaminergic differentiation of human embryonic stem cells. Stem Cells Dev. 14 (2005) 517-534
43. Ghosh S.S., Swerdlow R.H., Miller S.W., Sheeman B., Parker Jr. W.D., and Davis R.E. Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann. N. Y. Acad. Sci. 893 (1999) 176-191
44. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett Jr. J.P., Davis R.E., and Parker Jr. W.D. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40 (1996) 663-671
45. Gu M., Cooper J.M., Taanman J.W., and Schapira A.H. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol. 44 (1998) 177-186
46. Shults C.W., and Miller S.W. Reduced complex I activity in parkinsonian cybrids. Movement Disorders Supplement 13 (1998) 217
47. Borland M.K., Mohanakumar K.P., Rubinstein J.D., Keeney P.M., Xie J., Capaldi R., Dunham L.D., Trimmer P.A., and Bennett Jr. J.P. Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim. Biophys. Acta 1792 (2009) 68-74
48. Esteves A.R., Domingues A.F., Ferreira I.L., Januario C., Swerdlow R.H., Oliveira C.R., and Cardoso S.M. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion 8 (2008) 219-228
49. Onyango I.G., Tuttle J.B., and Bennett Jr. J.P. Brain-derived growth factor and glial cell line-derived growth factor use distinct intracellular signaling pathways to protect PD cybrids from H2O2-induced neuronal death. Neurobiol. Dis. 20 (2005) 141-154
50. Trimmer P.A., Borland M.K., Keeney P.M., Bennett Jr. J.P., and Parker Jr. W.D. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J. Neurochem. 88 (2004) 800-812
51. Trimmer P.A., Swerdlow R.H., Parks J.K., Keeney P., Bennett Jr. J.P., Miller S.W., Davis R.E., and Parker Jr. W.D. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp. Neurol. 162 (2000) 37-50
52. Swerdlow R.H., Parks J.K., Davis II J.N., Cassarino D.S., Trimmer P.A., Currie L.J., Dougherty J., Bridges W.S., Bennett Jr. J.P., Wooten G.F., and Parker W.D. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann. Neurol. 44 (1998) 873-881
53. Swerdlow R.H. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J. Neurosci. Res. 85 (2007) 3416-3428
54. Hoepken H.H., Gispert S., Azizov M., Klinkenberg M., Ricciardi F., Kurz A., Morales-Gordo B., Bonin M., Riess O., Gasser T., Kogel D., Steinmetz H., and Auburger G. Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp. Neurol. 212 (2008) 307-313
55. Piccoli C., Sardanelli A., Scrima R., Ripoli M., Quarato G., D'Aprile A., Bellomo F., Scacco S., De Michele G., Filla A., Iuso A., Boffoli D., Capitanio N., and Papa S. Mitochondrial Respiratory dysfunction in familiar Parkinsonism associated with PINK1 mutation. Neurochem. Res. (2008)
56. Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H.K., and Brundin P. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277 (2002) 38884-38894
57. Lotharius J., Falsig J., van Beek J., Payne S., Dringen R., Brundin P., and Leist M. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J. Neurosci. 25 (2005) 6329-6342
58. Paul G., Christophersen N.S., Raymon H., Kiaer C., Smith R., and Brundin P. Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line-studies in vitro and after intracerebral grafting in vivo. Mol. Cell. Neurosci. 34 (2007) 390-399
59. Schwartz P.H., Brick D.J., Stover A.E., Loring J.F., and Muller F.J. Differentiation of neural lineage cells from human pluripotent stem cells. Methods 45 (2008) 142-158
60. Donato R., Miljan E.A., Hines S.J., Aouabdi S., Pollock K., Patel S., Edwards F.A., and Sinden J.D. Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci. 8 (2007) 36
61. Hoffrogge R., Mikkat S., Scharf C., Beyer S., Christoph H., Pahnke J., Mix E., Berth M., Uhrmacher A., Zubrzycki I.Z., Miljan E., Volker U., and Rolfs A. 2-DE proteome analysis of a proliferating and differentiating human neuronal stem cell line (ReNcell VM). Proteomics 6 (2006) 1833-1847
62. Wood-Kaczmar A., Gandhi S., Yao Z., Abramov A.S., Miljan E.A., Keen G., Stanyer L., Hargreaves I., Klupsch K., Deas E., Downward J., Mansfield L., Jat P., Taylor J., Heales S., Duchen M.R., Latchman D., Tabrizi S.J., and Wood N.W. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS ONE 3 (2008) e2455
63. Deacon T., Dinsmore J., Costantini L.C., Ratliff J., and Isacson O. Blastula-stage stem cells can differentiate into dopaminergic and serotonergic neurons after transplantation. Exp. Neurol. 149 (1998) 28-41
64. Lee S.H., Lumelsky N., Studer L., Auerbach J.M., and McKay R.D. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat. Biotechnol. 18 (2000) 675-679
65. Kawasaki H., Mizuseki K., Nishikawa S., Kaneko S., Kuwana Y., Nakanishi S., Nishikawa S.I., and Sasai Y. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28 (2000) 31-40
66. Bjorklund L.M., Sanchez-Pernaute R., Chung S., Andersson T., Chen I.Y., McNaught K.S., Brownell A.L., Jenkins B.G., Wahlestedt C., Kim K.S., and Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2344-2349
67. Roy N.S., Cleren C., Singh S.K., Yang L., Beal M.F., and Goldman S.A. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12 (2006) 1259-1268
68. Kim J.H., Auerbach J.M., Rodriguez-Gomez J.A., Velasco I., Gavin D., Lumelsky N., Lee S.H., Nguyen J., Sanchez-Pernaute R., Bankiewicz K., and McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418 (2002) 50-56
69. Burbach J.P., and Smidt M.P. Molecular programming of stem cells into mesodiencephalic dopaminergic neurons. Trends Neurosci. 29 (2006) 601-603
70. Smidt M.P., and Burbach J.P. How to make a mesodiencephalic dopaminergic neuron. Nat. Rev. Neurosci. 8 (2007) 21-32
71. Van den Heuvel D.M., and Pasterkamp R.J. Getting connected in the dopamine system. Prog. Neurobiol. 85 (2008) 75-93
72. Kawasaki H., Suemori H., Mizuseki K., Watanabe K., Urano F., Ichinose H., Haruta M., Takahashi M., Yoshikawa K., Nishikawa S., Nakatsuji N., and Sasai Y. Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1580-1585
73. Zeng X., Cai J., Chen J., Luo Y., You Z.B., Fotter E., Wang Y., Harvey B., Miura T., Backman C., Chen G.J., Rao M.S., and Freed W.J. Dopaminergic differentiation of human embryonic stem cells. Stem Cells 22 (2004) 925-940
74. Buytaert-Hoefen K.A., Alvarez E., and Freed C.R. Generation of tyrosine hydroxylase positive neurons from human embryonic stem cells after coculture with cellular substrates and exposure to GDNF. Stem Cells 22 (2004) 669-674
75. Perrier A.L., Tabar V., Barberi T., Rubio M.E., Bruses J., Topf N., Harrison N.L., and Studer L. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 12543-12548
76. Vazin T., Chen J., Lee C.T., Amable R., and Freed W.J. Assessment of stromal-derived inducing activity in the generation of dopaminergic neurons from human embryonic stem cells. Stem Cells 26 (2008) 1517-1525
77. Yue F., Cui L., Johkura K., Ogiwara N., and Sasaki K. Induction of midbrain dopaminergic neurons from primate embryonic stem cells by coculture with Sertoli cells. Stem Cells 24 (2006) 1695-1706
78. Cho M.S., Lee Y.E., Kim J.Y., Chung S., Cho Y.H., Kim D.S., Kang S.M., Lee H., Kim M.H., Kim J.H., Leem J.W., Oh S.K., Choi Y.M., Hwang D.Y., Chang J.W., and Kim D.W. Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 3392-3397
79. Studer L., Tabar V., and McKay R.D. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat. Neurosci. 1 (1998) 290-295
80. Studer L., Csete M., Lee S.H., Kabbani N., Walikonis J., Wold B., and McKay R. Enhanced proliferation, survival, and dopaminergic differentiation of CNS preursors in lowered oxygen. J. Neurosci. 20 (2000) 7377-7383
81. Sanchez-Pernaute R., Studer L., Bankiewicz K.S., Major E.O., and McKay R.D. In vitro generation and transplantation of precursor-derived human dopamine neurons. J. Neurosci. Res. 65 (2001) 284-288
82. Panchision D.M., and McKay R.D. The control of neural stem cells by morphogenic signals. Curr. Opin. Genet. Dev. 12 (2002) 478-487
83. Snyder B.J., and Olanow C.W. Stem cell treatment for Parkinson's disease: an update for 2005. Curr. Opin. Neurol. 18 (2005) 376-385
84. Chung S., Shin B.S., Hwang M., Lardaro T., Kang U.J., Isacson O., and Kim K.S. Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro. Stem Cells 24 (2006) 1583-1593
85. Hermann A., Maisel M., Wegner F., Liebau S., Kim D.W., Gerlach M., Schwarz J., Kim K.S., and Storch A. Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem Cells 24 (2006) 949-964
86. Roussa E., Wiehle M., Dunker N., Becker-Katins S., Oehlke O., and Krieglstein K. Transforming growth factor beta is required for differentiation of mouse mesencephalic progenitors into dopaminergic neurons in vitro and in vivo: ectopic induction in dorsal mesencephalon. Stem Cells 24 (2006) 2120-2129
87. Liste I., Garcia-Garcia E., and Martinez-Serrano A. The generation of dopaminergic neurons by human neural stem cells is enhanced by Bcl-XL, both in vitro and in vivo. J. Neurosci. 24 (2004) 10786-10795
88. Liste I., Garcia-Garcia E., Bueno C., and Martinez-Serrano A. Bcl-XL modulates the differentiation of immortalized human neural stem cells. Cell Death Differ. 14 (2007) 1880-1892
89. Baghbaderani B.A., Mukhida K., Sen A., Hong M., Mendez I., and Behie L.A. Expansion of human neural precursor cells in large-scale bioreactors for the treatment of neurodegenerative disorders. Biotechnol. Prog. 24 4 (2008) 859-870
90. Mukhida K., Baghbaderani B.A., Hong M., Lewington M., Phillips T., McLeod M., Sen A., Behie L.A., and Mendez I. Survival, differentiation, and migration of bioreactor-expanded human neural precursor cells in a model of Parkinson disease in rats. Neurosurg. Focus 24 (2008) E8
91. Greschat S., Schira J., Kury P., Rosenbaum C., de Souza Silva M.A., Kogler G., Wernet P., and Muller H.W. Unrestricted somatic stem cells from human umbilical cord blood can be differentiated into neurons with a dopaminergic phenotype. Stem Cells Dev. 17 (2008) 221-232
92. Bianco P., Robey P.G., and Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2 (2008) 313-319
93. Nadri S., Soleimani M., Kiani J., Atashi A., and Izadpanah R. Multipotent mesenchymal stem cells from adult human eye conjunctiva stromal cells. Differentiation 76 (2008) 223-231
94. Nadri S., Soleimani M., Mobarra Z., and Amini S. Expression of dopamine-associated genes on conjunctiva stromal-derived human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 377 (2008) 423-428
95. Dezawa M., Kanno H., Hoshino M., Cho H., Matsumoto N., Itokazu Y., Tajima N., Yamada H., Sawada H., Ishikawa H., Mimura T., Kitada M., Suzuki Y., and Ide C. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J. Clin. Invest. 113 (2004) 1701-1710
96. Guo L., Yin F., Meng H.Q., Ling L., Hu-He T.N., Li P., Zhang C.X., Yu S., Duan D.S., and Fan H.X. Differentiation of mesenchymal stem cells into dopaminergic neuron-like cells in vitro. Biomed. Environ. Sci. 18 (2005) 36-42
97. Fu Y.S., Cheng Y.C., Lin M.Y., Cheng H., Chu P.M., Chou S.C., Shih Y.H., Ko M.H., and Sung M.S. Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. Stem Cells 24 (2006) 115-124
98. Tatard V.M., D'Ippolito G., Diabira S., Valeyev A., Hackman J., McCarthy M., Bouckenooghe T., Menei P., Montero-Menei C.N., and Schiller P.C. Neurotrophin-directed differentiation of human adult marrow stromal cells to dopaminergic-like neurons. Bone 40 (2007) 360-373
99. Suon S., Yang M., and Iacovitti L. Adult human bone marrow stromal spheres express neuronal traits in vitro and in a rat model of Parkinson's disease. Brain Res. 1106 (2006) 46-51
100. Trzaska K.A., Kuzhikandathil E.V., and Rameshwar P. Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells 25 (2007) 2797-2808
101. Trzaska K.A., and Rameshwar P. Current advances in the treatment of Parkinson's disease with stem cells. Curr. Neurovasc. Res. 4 (2007) 99-109
102. Fallahi-Sichani M., Soleimani M., Najafi S.M., Kiani J., Arefian E., and Atashi A. In vitro differentiation of cord blood unrestricted somatic stem cells expressing dopamine-associated genes into neuron-like cells. Cell Biol. Int. 31 (2007) 299-303
103. Zhang Z., Wang X., and Wang S. Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease. In Vitro Cell Dev. Biol. Anim. 44 (2008) 169-177
104. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007) 861-872
105. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., and Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 318 (2007) 1917-1920
106. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., Lerou P.H., Lensch M.W., and Daley G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451 (2008) 141-146
107. Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., Okita K., Mochiduki Y., Takizawa N., and Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26 (2008) 101-106
108. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., Clark A.T., and Plath K. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2883-2888
109. Zhao Y., Yin X., Qin H., Zhu F., Liu H., Yang W., Zhang Q., Xiang C., Hou P., Song Z., Liu Y., Yong J., Zhang P., Cai J., Liu M., Li H., Li Y., Qu X., Cui K., Zhang W., Xiang T., Wu Y., Zhao Y., Liu C., Yu C., Yuan K., Lou J., Ding M., and Deng H. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 3 (2008) 475-479
110. Hockemeyer D., Soldner F., Cook E.G., Gao Q., Mitalipova M., and Jaenisch R. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell 3 (2008) 346-353
111. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., and Melton D.A. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat. Biotechnol. 26 (2008) 795-797
112. Mikkelsen T.S., Hanna J., Zhang X., Ku M., Wernig M., Schorderet P., Bernstein B.E., Jaenisch R., Lander E.S., and Meissner A. Dissecting direct reprogramming through integrative genomic analysis. Nature 454 (2008) 49-55
113. Stadtfeld M., Nagaya M., Utikal J., Weir G., and Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 322 5903 (2008) 945-949
114. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., and Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 322 5903 (2008) 949-953
115. Carey B.W., Markoulaki S., Hanna J., Saha K., Gao Q., Mitalipova M., and Jaenisch R. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc. Natl. Acad. Sci. U. S. A. 106 1 (2009) 157-162
116. Eminli S., Utikal J.S., Arnold K., Jaenisch R., and Hochedlinger K. Reprogramming of neural progenitor cells into iPS cells in the absence of exogenous Sox2 expression. Stem Cells 26 10 (2008) 2467-2474
117. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., and Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458 7239 (2009) 771-775
118. Woltjen K., Michael I.P., Mohseni P., Desai R., Mileikovsky M., Hamalainen R., Cowling R., Wang W., Liu P., Gertsenstein M., Kaji K., Sung H.K., and Nagy A. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458 7239 (2009) 766-770
119. Soldner F., Hockemeyer D., Beard C., Gao Q., Bell G.W., Cook E.G., Hargus G., Blak A., Cooper O., Mitalipova M., Isacson O., and Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136 (2009) 964-977
120. H. Zhou, S. Wu, J.Y. Joo, S. Zhu, D.W. Han, T. Lin, S. Trauger, G. Bien, S. Yao, Y. Zhu, G. Siuzdak, H.R. Schöler, L. Duan, S. Ding, Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins, Cell Stem Cell 4 (5) (2009) 381-384.
121. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., and Daley G.Q. Disease-specific induced pluripotent stem cells. Cell 134 (2008) 877-886
122. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., Croft G.F., Saphier G., Leibel R., Goland R., Wichterle H., Henderson C.E., and Eggan K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321 (2008) 1218-1221
123. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., Broccoli V., Constantine-Paton M., Isacson O., and Jaenisch R. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5856-5861
124. Aoi T., Yae K., Nakagawa M., Ichisaka T., Okita K., Takahashi K., Chiba T., and Yamanaka S. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 321 (2008) 699-702
125. Aasen T., Raya A., Barrero M.J., Garreta E., Consiglio A., Gonzalez F., Vassena R., Bilic J., Pekarik V., Tiscornia G., Edel M., Boue S., and Belmonte J.C. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat. Biotechnol. 26 (2008) 1276-1284
126. Loh Y.H., Agarwal S., Park I.H., Urbach A., Huo H., Heffner G.C., Kim K., Miller J.D., Ng K., and Daley G.Q. Generation of induced pluripotent stem cells from human blood. Blood 113 (2009) 5476-5479
127. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J., Healy D.G., Holton J.L., Revesz T., and Wood N.W. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (2005) 415-416
128. Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S., Halter C.A., Michaels V.E., Reed T., Rudolph A., Shults C.W., Singleton A., and Foroud T. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365 (2005) 410-412
129. Di Fonzo A., Rohe C.F., Ferreira J., Chien H.F., Vacca L., Stocchi F., Guedes L., Fabrizio E., Manfredi M., Vanacore N., Goldwurm S., Breedveld G., Sampaio C., Meco G., Barbosa E., Oostra B.A., and Bonifati V. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365 (2005) 412-415
130. Kachergus J., Mata I.F., Hulihan M., Taylor J.P., Lincoln S., Aasly J., Gibson J.M., Ross O.A., Lynch T., Wiley J., Payami H., Nutt J., Maraganore D.M., Czyzewski K., Styczynska M., Wszolek Z.K., Farrer M.J., and Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76 (2005) 672-680
131. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7 (2006) 306-318